The creation and refinement of drug susceptibility tests (DSTs) are central to CPTR’s mission to accelerate the development of new and more effective tuberculosis drug regimens. Properly utilized, DSTs play a crucial role in improving the management of TB patients, facilitating drug development and rational use of new TB drug regimens, and better understanding the global burden of drug-resistant TB. They do so by determining if a patient has a form of TB that is drug-resistant. Treating large populations without the use of these tests could lead to the growth and spread of dangerously drug-resistant TB strains.
The objective of CPTR’s Rapid Drug Susceptibility Testing (RDST) Consortium is to speed the development of a WHO STAG-endorsed, clinically useful in vitro diagnostic assay specific to rapid drug susceptibility testing of TB, and inform drug development and the rationale for new drug regimens. This work is done through generating and researching molecular data to drive the development of molecular DST assays, facilitating the development of rapid TB DSTs to meet target product profiles, improving the strategies for surveillance of TB drug resistance, and developing models to provide insight on the impact of various components to TB drug regimens and trajectories with and without DST intervention.
Among the consortium’s many initiatives is the creation of the Relational Sequencing TB Data Platform, or ReSeqTB. The product of an unprecedented international partnership, the ReSeqTB collects global TB patient data otherwise dispersed among multiple private and public databases. A centralized and foundational resource, ReSeqTB is a capable of helping to identify correlations between M.tb mutations and clinically relevant resistance, aiding in the development of new rapid drug susceptibility tests, facilitating nternational research and collaboration, and, eventually, directly enabling sequencing data interpretation for personalized patient care.
The Data Platform